Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-κB induction

Journal of Experimental Medicine

Volumn 186, Issue 5, 1997, Pages 731-737

  Sugano, Naoyuki ^a,c   Chen, Weiping ^a   Roberts, M Luisa ^a,d   Cooper, Neil R ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b IMM 19 ^*  (United States)

^c NIHON UNIVERSITY   (Japan)

^d ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; TRANSCRIPTION FACTOR;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; EPSTEIN BARR VIRUS; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION;

ASPIRIN; B-LYMPHOCYTES; DNA PROBES; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; NAPHTHALENES; NF-KAPPA B; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; RECEPTORS, COMPLEMENT 3D; RECEPTORS, VIRUS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR RELB; TRANSCRIPTION FACTORS;

EID: 0030823424     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.186.5.731     Document Type: Article

References (39)

1. Nemerow, G.R., A.T. Luxembourg, and N.R. Cooper. 1994. CD21/CR2: its role in EBV infection and immune function. Epstein Barr Virus Rep. 1:59-64.
2. Fearon, D.T., and R.H. Carter. 1995. The CD19/CR2/ TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 13:127-149.
3. Nemerow, G.R., R.A. Houghten, M.D. Moore, and N.R. Cooper. 1989. Identification of the epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell. 56:369-377.
4. Miyamoto, S., and M. Verma. 1995. REL/NF-κB/IκB story. Adv. Cancer Res. 66:255-292.
5. Sen, R., and D. Baltimore. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:705-716.
6. Luxembourg, A.T., and N.R. Cooper. 1994. T cell dependent B cell activating properties of antibody-coated small latex beads: a new model for B cell activation. J. Immunol. 153: 604-614.
7. Nemerow, G.R., and N.R. Cooper. 1981. Isolation of Epstein-Barr virus and studies of its neutralization by human IgG and complement. J. Immunol. 127:272-278.
8. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer. 33:27-32.
9. Luxembourg, A.T., and N.R. Cooper. 1994. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and Epstein-Barr virus. J. Immunol. 153:4448-4457.
10. Tanner, J., Y. Whang, J. Sample, A. Sears, and E. Kieff. 1988. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J. Virol. 62:4452-4464.
11. Roberts, M.L., A.T. Luxembourg, and N.R. Cooper. 1996. Epstein-Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection. J. Gen. Virol. 77:3077-3085.
12. Chen, W., and N.R. Cooper. 1996. Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-κB activity. J. Virol. 70:4849-4853.
13. Allday, M.J., D.H. Crawford, and B.E. Griffin. 1989. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J. Gen. Virol. 70:1755-1764.
14. Rooney, C., J.G. Howe, S.H. Speck, and G. Miller. 1989. Influences of Burkitts'lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3-HR-1 strain of Epstein-Barr virus. J. Virol. 63:1531-1539.
15. Scala, G., I. Quinto, M.R. Ruocco, M. Mallardo, C. Ambrosino, B. Squitieri, P. Tassone, and S. Venuta. 1993. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J. Virol. 67:2853-2861.
16. Paine, E., R.I. Scheinman, A.S. Baldwin, and N. Raab-Traub. 1995. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kB/Rel family proteins. J. Virol. 69:4572-4576.
17. Nemerow, G.R., R. Wolfert, M.E. McNaughton, and N.R. Cooper. 1985. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor. J. Virol. 55:347-351.
18. Nemerow, G.R., M.F.E. Siaw, and N.R. Cooper. 1986. Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J. Virol. 58:709-712.
19. Moore, M.D., R.G. DiScipio, N.R. Cooper, and G.R. Nemerow. 1989. Hydrodynamic, electron microscopic and ligand binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J. Biol. Chem. 264:20576-20582.
20. Chen, Z., J. Hagler, V.J. Palombella, F. Melandri, D. Scherer, D. Ballard, and T. Maniatis. 1995. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev. 9:1586-1597.
21. Ghosh, S., and D. Baltimore. 1996. Activation in vitro of NF-kB by phosphorylation of its inhibitor IkB. Nature (Lond.). 344:678-682.
22. Gopalakrishna, R., Z.H. Chen, and U. Gundimeda. 1992. Irreversible oxidative inactivation of protein kinase C by photosensitive inhibitor calphostin C. FEBS Lett. 314:149-154.
23. Kobayashi, E., H. Nakano, M. Morimoto, and T. Tamaoki. 1989. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:548-553.
24. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-kB by sodium salicylate and aspirin. Science (Wash. DC). 265:956-959.
25. Grilli, M., M. Pizzi, M. Memo, and P. Spano. 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kB activation. Science (Wash. DC). 274:1383-1385.
26. Schreck, R., P. Rieber, and P.A. Baeuerle. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1. EMBO (Eur. Mol. Biol. Organ.) J. 10:2247-2258.
27. Sample, J., M. Hummel, D. Braun, M. Birkenbach, and E. Kieff. 1986. Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc. Natl. Acad. Sci. USA. 83:5096-5100.
28. Sinclair, A.J., and P.J. Farrell. 1995. Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J. Virol. 69:5461-5468.
29. Nemerow, G.R., and N.R. Cooper. 1984. Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology. 132:186-198.
30. Grilli, M., J.J.-S. Chiu, and M.J. Lenardo. 1993. NF-kB and Rel: participants in a multiform transcriptional regulatory system. Int. Rev. Cytol. 143:1-62.
31. Peng, M., and E. Lundgren. 1992. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene. 7: 1775-1782.
32. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO (Eur. Mol. Biol. Organ.) J. 13: 3321-3328.
33. Rosen, C.A., J.G. Sodroski, and W.A. Haseltine. 1995. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell. 41:813-823.
34. Hansen, S.K., L. Guerrin, and F. Blasi. 1994. Differential DNA sequence specificity and regulation of HIV-1 enhancer activity by cRel-RelA transcription factor. J. Biol. Chem. 269:22230-22237.
35. Kunsch, C., S.M. Ruben, and C.A. Rosen. 1992. Selection of optimal kB/Rel DNA-binding motifs: interaction of both subunits of NF-kB with DNA is required for transcriptional activation. Mol. Cell. Biol. 12:4412-4421.
36. Fujita, T., G.P. Nolan, S. Ghosh, and D. Baltimore. 1992. Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kB. Genes Dev. 6:775-787.
37. Beg, A.A., and D. Baltimore. 1996. An essential role for NF-kB in preventing TNF-α-induced cell death. Science (Wash. DC). 274:782-783.
38. Wang, C.-Y., M.W. Mayo, and A.S.J. Baldwin. 1996. TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Wash. DC). 274:784-787.
39. Antwerp, D.J.V., S.J. Martin, T. Kafri, D.R. Green, and I.M. Verma. 1996. Suppression of TNF-α-induced apoptosis by NF-kB. Science (Wash. DC). 274:787-789.